Comparisons of the effects of different flaxseed products consumption on lipid profiles, inflammatory cytokines and anthropometric indices in patients with dyslipidemia related diseases: systematic review and a dose-response meta-analysis of randomized controlled trials.
Comparisons of the effects of different flaxseed products consumption on lipid profiles, inflammatory cytokines and anthropometric indices in patients with dyslipidemia related diseases: systematic review and a dose-response meta-analysis of randomized controlled trials.
复制标题
不同亚麻籽产品摄入量对血脂异常相关疾病患者血脂、炎症细胞因子和人体测量指数影响的比较：系统评价和随机对照的剂量反应荟萃分析
DOI：
10.1186/s12986-021-00619-3
复制
发表时间：
2021-10-11
影响因子：
4.5
通讯作者：
Sun G
中科院分区：
文献类型：
--
作者：
Yang C;Xia H;Wan M;Lu Y;Xu D;Yang X;Yang L;Sun G
亚麻籽因其富含亚麻酸、木脂素和膳食纤维而被广泛用作功能性食品。本系统综述和随机对照试验（rct）的剂量反应荟萃分析首次评估了不同亚麻籽产品（全亚麻籽、油和木脂素）对血脂异常相关疾病患者的脂质谱、炎症和人体测量参数的影响。在PubMed， Embase, Cochrane Central， Scopus和Web of Science中进行了从成立日期到2020年1月的文献检索。加权平均差异与95%置信区间（CI）使用固定或随机效应模型合并。纳入31项随机对照试验，涉及1,698名受试者。本荟萃分析显示，食用亚麻籽对血脂异常相关疾病患者的血清TC、LDL-C、TG、载脂蛋白B和IL-6有总体有益影响，但对载脂蛋白A、HDL-C、hs-CRP、CRP和人体测量指标没有影响。但不同亚麻籽制品的效果有明显差异。全亚麻籽补充显著降低TC(−11.85 mg / dl, 95% CI 20.12−−3.57,P = 0.005),低密度脂蛋白(−10.51 mg / dl, 95% CI 14.96−−6.06,P < 0.001), TG(−19.77 mg / dl, 95% CI 33.61−−5.94,P = 0.005),载脂蛋白B(−5.73 mg / dl, 95% CI 7.53−−3.93,P < 0.001), TC / hdl - c(−0.10,95% CI 0.19−−0.003,P = 0.044)和体重(−0.40公斤,95% CI 0.76−−0.05,P = 0.027);补充木脂素显著降低TC （- 17.86 mg/dl, P = 0.004）、LDL-C （- 15.47 mg/dl, P < 0.001）和TC/HDL-C （- 0.45 mg/dl, P = 0.04）。虽然补充亚麻籽油对血脂没有这种降低作用，但荟萃分析显示其对IL-6 （- 0.35 pg/ml, P = 0.033）和hs-CRP （- 1.54 mg/l, P = 0.004）有降低作用。亚组分析显示，与国家和规定的干预时间无关，全亚麻籽降低了TC、LDL-C和TG水平，但当全亚麻籽剂量≤30 g/天时（TC: WMD−13.61 mg/mL; LDL-C: WMD−10.52 mg/mL; TG: WMD−23.52 mg/mL）更为明显，而剂量≤30 g/天时则不明显。此外，全亚麻籽剂量与c反应蛋白绝对变化呈线性关系（P = 0.036），与IL-6呈非线性关系（P < 0.001）。亚麻籽干预对血脂异常相关疾病患者的脂质谱、炎症细胞因子和人体测量指标均有积极影响。其中，整个亚麻籽和木脂素具有降低血脂的重要作用，而亚麻籽油主要具有抗炎作用。对于混合性血脂异常患者和BMI为bbb25的患者，当剂量< 30 mg/d的全亚麻籽食用时，脂质和体重均显著降低。在线版本包含补充材料，可在10.1186/s12986-021-00619-3获得。
Flaxseed is widely used as a functional food for its rich sources of linolenic acid, lignans and dietary fibers in the world. This systematic review and dose–response meta-analysis on randomized controlled trials (RCTs) is first to evaluate effects of different flaxseed products (whole flaxseed, oil and lignans) on lipid profiles, inflammatory and anthropometric parameters in patients with dyslipidemia related diseases. Literature search was performed in PubMed, Embase, Cochrane Central, Scopus, and Web of Science from the inception dates to January, 2020. Weighted mean differences with the 95% confidence interval (CI) were pooled using fix or random-effects models. Thirty-one RCTs involving 1,698 participants were included. The present meta-analysis revealed that flaxseed consumption had an overall beneficial effect on serum TC, LDL-C, TG, apo B and IL-6 in patients with dyslipidemia related diseases, but not on apo A, HDL-C, hs-CRP, CRP and anthropometric indices. However, different flaxseed products showed obviously different effects. Whole flaxseed supplementation significantly reduced TC (− 11.85 mg/dl, 95% CI − 20.12 to − 3.57, P = 0.005), LDL-C (− 10.51 mg/dl, 95% CI − 14.96 to − 6.06, P < 0.001), TG (− 19.77 mg/dl, 95% CI − 33.61 to − 5.94, P = 0.005), apolipoprotein B (− 5.73 mg/dl, 95% CI − 7.53 to − 3.93, P < 0.001), TC/HDL-C (− 0.10, 95% CI − 0.19 to − 0.003, P = 0.044) and weight (− 0.40 kg, 95% CI − 0.76 to − 0.05, P = 0.027); Lignans supplementation significantly reduced TC (− 17.86 mg/dl, P = 0.004), LDL-C (− 15.47 mg/dl, P < 0.001) and TC/HDL-C (− 0.45, P = 0.04). Although flaxseed oil supplementation had no such lowering-effect on lipid, meta-analysis revealed its lowering-effect on IL-6 (− 0.35 pg/ml, P = 0.033) and hs-CRP (− 1.54 mg/l, P = 0.004). Subgroup analysis revealed that whole flaxseed decreased TC, LDL-C and TG levels irrespective of country and the intervention time prescribed, but was more pronounced when the dose of whole flaxseed was ≤ 30 g/day (TC: WMD − 13.61 mg/mL; LDL-C: WMD − 10.52 mg/mL; TG: WMD − 23.52 mg/mL), rather not a dose > 30 g/day. Moreover, a linear relationship between dose of whole flaxseed and absolute changes in C-reactive protein (P = 0.036) and a nonlinear relationship between with IL-6 (P < 0.001) were detected. Flaxseed intervention suggested the positive effects on lipid profiles, inflammatory cytokines and anthropometric indices in patients with dyslipidemia related diseases. Of these, whole flaxseed and lignans play an important role in reducing blood lipid, while flaxseed oil mainly plays in anti-inflammatory. Lipid- and weight-lowering was significant when whole flaxseed was consumed at doses < 30 mg/d, for lipid status with mixed dyslipidemia and patients with BMI > 25. The online version contains supplementary material available at 10.1186/s12986-021-00619-3.
登录
查看更多内容
影响因子：
5.9
作者：
Buckley JD;Howe PRC
通讯作者：
Howe PRC
影响因子：
4.5
作者：
Arjmandi, BH;Khan, DA;Derman, R
通讯作者：
Derman, R
影响因子：
3.6
作者：
Gillingham, Leah G.;Gustafson, Jennifer A.;Jones, Peter J. H.
通讯作者：
Jones, Peter J. H.
影响因子：
4.4
作者：
Akrami, Atefeh;Nikaein, Farzad;Yarmohammadi, Hassan
通讯作者：
Yarmohammadi, Hassan
影响因子：
4.9
作者：
Banuls, C.;Rovira-Llopis, S.;Hernandez-Mijares, A.
通讯作者：
Hernandez-Mijares, A.